MedTrace Logo

F16IL2 in Combination With Nivolumab in Patients With Non-small Cell Lung Cancer

NCT05468294 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-07-21

No results posted yet for this study

Summary

Prospective, open label, non-randomized, phase I/IIb study of F16IL2 in combination with Nivolumab.

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

F16IL2

F16IL2 infusion will be always administered in 180 minutes i.v. on day 1, 8, 15 and 22 of each 28-days cycle.

DRUG

Nivolumab, fixed dose

Patients will receive 3 mg/kg of Nivolumab as a 60 minutes i.v. infusion on day 1 and day 15 of each 28-days cycle.

Sponsors & Collaborators

  • Philogen S.p.A.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-09
Primary Completion
2021-12-31
Completion
2022-07-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468294 on ClinicalTrials.gov